Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
Authors:
- Frederic AmantFAFrederic Amant
- Patrick BertelootPBPatrick Berteloot
- Giovanni ScambiaGSGiovanni Scambia
- Ignace VergoteIVIgnace Vergote
- 1 March 2003
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 88 (3) , 266-269
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Phase I Study of Gemcitabine and Liposomal Doxorubicin in Relapsed Ovarian CancerOncology, 2002
- Second-line treatment of ovarian cancer with single-agent gemcitabineSeminars in Oncology, 2002
- The role of gemcitabine-based doublets in the management of ovarian carcinoma.Seminars in Oncology, 2002
- Future directions in the treatment of ovarian cancerSeminars in Oncology, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Gemcitabine in ovarian cancerSeminars in Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI: Journal of the National Cancer Institute, 1994